Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy

Journal of Viral Hepatitis

Volumn 21, Issue 8, 2014, Pages

  Chen, Chien Hung ^a   Hu, Tsung Hui ^a   Hung, Chao Hung ^a   Wang, Jing Houng ^a   Lu, Sheng Nan ^a   Lee, Chuan Mo ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

adefovir; entecavir; hepatitis B virus; lamivudine; resistance; virological response

Indexed keywords

ENTECAVIR; LAMIVUDINE; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; HEPATITIS B, CHRONIC; ISOLATION AND PURIFICATION; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84903816937     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12239     Document Type: Article

References (29)

1. Lee WM,. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745. (Pubitemid 27527771)
2. Chen DS,. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262: 369-370.
3. Liaw YF,. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29 (Suppl 1): 100-107.
4. Lee CM, Lu SN, Changchien CS, et al,. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999; 86: 1143-1150.
5. Gish RG, Lok AS, Chang TT, et al,. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 33: 1437-1444. (Pubitemid 350029745)
6. Chang TT, Lai CL, Kew Yoon S, et al,. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430.
7. Tenney DJ, Rose RE, Baldick CJ, et al,. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
8. Sherman M, Yurdaydin C, Simsek H, et al,. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48: 99-108. (Pubitemid 351975535)
9. Sherman M, Yurdaydin C, Sollano J, et al,. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-2049. (Pubitemid 43816960)
10. Tenney DJ, Pokornowski K, Rose RE, et al,. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008; 2: S302-S303.
11. Reijnders JGP, Deterding K, Petersen J, et al,. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52: 493-500.
12. Keeffe EB, Zeuzem S, Koff RS, et al,. Report of an international workshop: roadmap for management of patients receiving oral therapy of chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-897. (Pubitemid 47127032)
13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
14. Zoutendijk R, Reijnders JGP, Brown A, et al,. Entecavir Treatment for Chronic Hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology 2011; 54: 443-451.
15. Mizokami M, Nakano T, Orito E, et al,. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 1999; 450: 66-71. (Pubitemid 29206714)
16. Lee CM, Chen CH, Lu SN, et al,. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol 2003; 1: 95-101.
17. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL,. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011; 106: 1264-1271.
18. Ono A1, Suzuki F, Kawamura Y, et al,. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol 2012; 57: 508-514.
19. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ,. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010; 53: 449-454.
20. Cho SW, Koh KH, Cheong JY, et al,. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. J Viral Hepat 2010; 17: 171-177.
21. Chen CH, Wang JH, Lu SN, et al,. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir resistant mutants. Antivir Ther 2012; 17: 701-709.
22. Chen CH, Wang JH, Lu SN, et al,. Incidence and predictors of adefovir resistance in patients with or without lamivudine-resistant HBV treated with adefovir-a four-year experience. Liver Int 2011; 31: 206-214.
23. van Bömmel F, de Man RA, Wedemeyer H, et al,. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
24. Patterson SJ, George J, Strasser SI, et al,. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011; 60: 247-254.
25. Baran B, Soyer OM, Ormeci AC, et al,. Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. Antimicrob Agents Chemother 2013; 57: 1790-1796.
26. Brunelle MN, Jacquard AC, Pichoud C, et al,. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-1398. (Pubitemid 40770292)
27. Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL,. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 2009; 50: 674-683.
28. Hsu CW, Chao YC, Lee CM, Chang TT, Chen YC,. Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24. BMC Gastroenterol 2012; 12: 178-186.
29. Lee GH, Aung MO, Dan YY, et al,. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance? J Med Virol 2013; 85: 26-33.